Global clinical trial activity continues to expand in both scale and complexity, yet enrollment performance remains one of the most persistent operational challenges facing sponsors and CROs. Industry data indicates that approximately 80 percent of clinical trials experience delays are prematurely terminated due to challenges in patient recruitment, reflecting ongoing pressure at the site level.
Many sites struggle to meet enrollment targets amid staffing constraints, competition from overlapping studies, and increasingly complex protocols. Additional analyses show that a significant proportion of sites enroll fewer patients than initially projected, reinforcing a growing gap between trial design expectations and site-level operations. For CROs responsible for study delivery, these trends highlight the critical importance of proactive, structured site engagement as a core driver of enrollment performance and the successful completion of evaluable participants needed to generate meaningful study outcomes.
Understanding how site engagement directly influences enrollment outcomes is essential to closing this gap and improving study execution.
From my experience as a Clinical Trial Manager (CTM) at Linical, site engagement is most effective when it is treated as a continuous partnership rather than a series of transactional interactions. We’ve observed that effective engagement relies on consistent communication between sponsors, CROs and sites, as well as strong cross-functional alignment within the CRO itself. CTMs and Clinical Research Associates (CRAs) feel supported, aligned and confident within their study teams, we see that strength carried into site interactions, often reinforcing trust and sustained site engagement throughout the duration of the study.
Engaged sites demonstrate early interest during feasibility, balance study priorities across competing trials, proactively address recruitment barriers, and communicate issues early and often. Principal Investigator (PI) involvement remains a key indicator of site engagement throughout the study lifecycle. In contrast, poor engagement often presents as delayed feasibility responses, low responsiveness during site activation, passive enrollment behavior, and minimal PI involvement. The CTM should identify early engagement signals and communicate this information as a study progresses.
From my experience as a CTM, studies with strong site engagement not only enroll more predictably but are better positioned to retain participants and collect complete, high‑quality data through study closeout.
Three foundational practices apply across studies and therapeutic areas: early and meaningful site involvement, clear and consistent communication, and relationship‑centered study management.
Early and meaningful site involvement can include thoughtful feasibility discussions, two-way dialogue on competing trials, realistic enrollment potential, and operational constraints. Early communication sets mutual expectations before site activation, which gives the CRA a reference point during Site Qualification. Furthermore, study teams appreciate predictable communication cadence, tailored messaging, and consistent instructions from the CRO, sponsor and vendors. Ultimately, treating sites as long‑term partners rather than transactional vendors strengthens engagement and enrollment performance.
Effective site management must directly support enrollment execution in addition to general communication and relationship management. Enrollment‑focused engagement tactics help sites translate feasibility assumptions into actionable enrollment plans, identify barriers early, and adapt approaches as real‑world challenges emerge. For CROs, this requires a shift from monitoring enrollment metrics to actively partnering with sites to influence outcomes.
Enrollment success is inherently site specific. Differences in patient populations, referral networks, staffing models, and competing studies limit the effectiveness of a one‑size‑fits‑all enrollment strategy.
CRO-let site engagement should include:
Enrollment plans should reflect how a site operates, as sites are more likely to take ownership of recruitment expectations and proactively communicate risks.
Technology can enable, but not replace, effective engagement. Data visibility through real‑time dashboards allows teams to monitor enrollment and screening trends, identify drop‑off points, and distinguish between lagging and high‑performing sites. Used appropriately, these tools guide productive conversations
Site communication and collaboration tools can be housed in centralized platforms for training materials, FAQs and study updates, reducing email overload, and version control amongst study teams. Sponsors and CROs can collaborate in real time outside of scheduled meetings.
Participant facing technology has become standard in site engagement strategy, with sites using trusted recruitment platforms and utilizing wearables, ePro, or decentralized elements which reduce site burden. Site and participant training are equally as important. Engagement is most effective when site staff actively support participants during training, ensuring understanding of study requirements and reducing downstream errors. Success lies in site staff sitting with the participants while they complete training. This physical presence reduces training errors and confirms understanding of study instructions.
What I consistently see across studies is that sites are not disengaged by choice, but constrained by capacity, competing priorities, and unclear expectations. Industry discussions on participant readiness emphasize that enrollment challenges frequently stem from a gap between identifying medically eligible patients and ensuring those patients are prepared to participate. Without sufficient education, support, and clarity around study expectations, patients may disengage despite meeting eligibility criteria, contributing to screen failures and early dropouts.
Protocol complexity compounds these challenges by increasing visit burden and patient hesitation. Misalignment between enrollment expectations and site reality, particularly when feasibility assumptions remain unchanged despite emerging data, further undermines transparency and risk proportionate trial management.
Internal CRO handoffs, including CTM transitions, can introduce additional engagement risk if knowledge transfer is incomplete. Loss of context around site constraints or patient readiness discussions may lead to inconsistent messaging and weakened site relationships.
Improving enrollment performance requires CROs to move from reactive problem‑solving to proactive engagement models that account for both site realities and patient readiness.
At Linical we frequently see that enabling CTMs to surface enrollment and retention risks early allows Project Managers and Project Directors to intervene before assumptions no longer hold. When CTMs are empowered to escalate feasibility concerns, recommend course corrections, and coordinate recovery discussions, enrollment decisions can be made more effectively and in alignment with real‑time site and patient realities.
Enrollment and engagement challenges rarely sit within a single function. CROs that align clinical operations, feasibility, recruitment, and vendors around shared enrollment goals are better positioned to respond to site‑level constraints. Coordinated oversight helps ensure that recruitment tools, vendor support, and site guidance reflect actual protocol burden and patient readiness considerations, reinforcing consistent and fit‑for‑purpose trial conduct.
From a CTM perspective, proactive engagement is most effective when escalation is positioned as a support mechanism rather than a signal of failure. Clear, non‑punitive escalation mechanisms encourage timely communication of enrollment risks, including staffing constraints or patient readiness barriers. This transparency supports participant protection and proactive risk management.
Replacing one‑time surveys with continuous feedback loops allows CROs to capture real‑time insight into site and participant experience. Regular enrollment discussions and screening trend reviews help identify patient readiness barriers earlier and improve screening‑to‑enrollment conversion.
Engagement is measurable and actionable. Potential indicators include:
These metrics help determine whether engagement approaches are effectively supporting enrollment outcomes.
The future of site engagement continues to evolve as hybrid and decentralized models reshape how studies are conducted and supported. Increasing emphasis on site experience metrics, combined with more advanced data and predictive analytics, is enabling trial teams to identify potential engagement risks earlier and intervene more proactively. As these models mature, CROs and sites will be challenged to balance operational flexibility with consistency, clarity, and sustained relationship management.
Within this evolving landscape, participant readiness is emerging as an important complementary consideration rather than a standalone strategy. As decentralized elements and digital tools become more common, ensuring that patients understand study expectations, visit requirements, and long‑term commitment will be increasingly important to support enrollment conversion and retention. For CROs, this represents an opportunity to further strengthen site engagement by providing sites with the guidance, tools, and support needed to prepare participants effectively, without adding burden or shifting responsibility.
Together, these trends reinforce the need for CTMs to continue expanding their skill sets to include data literacy, cross‑functional coordination, relationship management, and change leadership, all of which are critical to navigating the next phase of site engagement.
Enrollment success is multifaceted. Sustainable enrollment comes from consistent, transparent and respectful site partnerships. CROs that invest in engagement through people, processes and tools gain a long-term competitive advantage. In my experience, the CROs that stand apart are those that invest not only in getting patients enrolled, but in ensuring sites are equipped to support participants through study completion.
How does your current engagement approach support or limit site success?
References
Author:
Alaina Dobos
Senior Clinical Trial Manager